Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

R Perets,J Bar,D W Rasco,M-J Ahn,K Yoh,D-W Kim,A Nagrial,M Satouchi, D H Lee,D R Spigel,D Kotasek,M Gutierrez,J Niu,S Siddiqi,X Li,J Cyrus, A Chackerian,A Chain, R A Altura,B C Cho

Annals of Oncology（2021）

引用 49|浏览92

暂无评分

摘要

•Quavonlimab, a novel anti-CTLA-4 antibody, in combination with pembrolizumab was investigated in a first-in-human study.•The combination therapy was safe and tolerable and showed antitumor activity in patients with advanced NSCLC.•Data from this study led to a recommended phase II dose of 25 mg Q6W for quavonlimab when used with pembrolizumab.

查看译文

关键词

non-small-cell lung cancer,quavonlimab,MK-1308,CTLA-4,pembrolizumab,immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要